Search results
Results from the WOW.Com Content Network
Osteoporosis, including drug- and cancer-related osteoporosis, giant cell tumour of bone and hypercalcaemia of malignancies Hypercholesterolaemia, cataract, urinary retention, hypocalcaemia, osteonecrosis of the jaw and anaphylaxis.
Estramustine phosphate, the only dual hormonal and cytostatic antineoplastic agent to have been marketed. A normustine and phosphate ester of estradiol. Used in the treatment of prostate cancer. This is a list of dual hormonal and cytostatic antineoplastic agents.
Generally, drugs outlined within the ATC code L01 should be included in this category. Please see WP:PHARM:CAT for more information. Wikimedia Commons has media related to Antineoplastic agents .
The table below gives an overview of databases for that serve specifically for oncogenomic research. Note that this is not a comprehensive list and does not contain databases that have a generic focus. You may find databases containing cancer data among the List of biological databases or Microarray databases.
ATC code L01 Antineoplastic agents is a therapeutic subgroup of the Anatomical Therapeutic Chemical Classification System, a system of alphanumeric codes developed by the World Health Organization (WHO) for the classification of drugs and other medical products.
This is a list of chemotherapeutic agents, also known as cytotoxic agents or cytostatic drugs, that are known to be of use in chemotherapy for cancer.This list is organized by type of agent, although the subsections are not necessarily definitive and are subject to revision.
Tissue-agnostic cancer drugs are antineoplastic drugs that treat cancers based on the mutations that they display, instead of the tissue type in which they appear. [ 1 ] [ 2 ] [ 3 ] Tissue-agnostic drugs that have been approved for medical use include Pembrolizumab , Larotrectinib , Selpercatinib , Entrectinib , and Pralsetinib .
This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.